CLL stage and tumor cell features
| Patient ID no. . | Binet stage at diagnosis . | Zap70, % . | CD38, % . | IGHV mutational status . |
|---|---|---|---|---|
| 177 | A | 0 | 0 | M |
| 244* | A | 16 | 2 | M |
| 259 | A | 2 | 4 | M |
| 264 | A | 88 | 20 | M |
| 269 | B | 1 | 1 | M |
| 317 | A | 9 | 0 | M |
| 326 | B | 8 | 2 | M |
| 327 | A | 46 | 42 | M |
| 333* | A | 1 | 1 | M |
| 344 | A | 31 | 60 | M |
| 357 | A | 5 | 36 | M |
| 374 | A | 0 | 3 | M |
| 379 | A | 0 | 1 | M |
| 399 | A | 2 | 0 | M |
| 406 | A | 1 | 0 | M |
| 413 | A | 3 | 3 | M |
| 416 | A | 0 | 7 | M |
| 420 | A | 1 | 100 | M |
| 418 | C | 11 | 67 | M |
| 255 | C | 25 | 8 | U |
| 284* | B | 48 | 12 | U |
| 288* | A | 61 | 71 | U |
| 291 | NA | 88 | 18 | U |
| 293* | A | 29 | 16 | U |
| 305* | C | 65 | 9 | U |
| 315 | A | 15 | 8 | U |
| 328 | A | 16 | 23 | U |
| 350 | A | 63 | 95 | U |
| 376 | A | 9 | 63 | U |
| 383 | A | 17 | 24 | U |
| 385 | A | 11 | 36 | U |
| 394 | A | 25 | 96 | U |
| 409 | B | 77 | 56 | U |
| 415 | A | 1 | 51 | U |
| Patient ID no. . | Binet stage at diagnosis . | Zap70, % . | CD38, % . | IGHV mutational status . |
|---|---|---|---|---|
| 177 | A | 0 | 0 | M |
| 244* | A | 16 | 2 | M |
| 259 | A | 2 | 4 | M |
| 264 | A | 88 | 20 | M |
| 269 | B | 1 | 1 | M |
| 317 | A | 9 | 0 | M |
| 326 | B | 8 | 2 | M |
| 327 | A | 46 | 42 | M |
| 333* | A | 1 | 1 | M |
| 344 | A | 31 | 60 | M |
| 357 | A | 5 | 36 | M |
| 374 | A | 0 | 3 | M |
| 379 | A | 0 | 1 | M |
| 399 | A | 2 | 0 | M |
| 406 | A | 1 | 0 | M |
| 413 | A | 3 | 3 | M |
| 416 | A | 0 | 7 | M |
| 420 | A | 1 | 100 | M |
| 418 | C | 11 | 67 | M |
| 255 | C | 25 | 8 | U |
| 284* | B | 48 | 12 | U |
| 288* | A | 61 | 71 | U |
| 291 | NA | 88 | 18 | U |
| 293* | A | 29 | 16 | U |
| 305* | C | 65 | 9 | U |
| 315 | A | 15 | 8 | U |
| 328 | A | 16 | 23 | U |
| 350 | A | 63 | 95 | U |
| 376 | A | 9 | 63 | U |
| 383 | A | 17 | 24 | U |
| 385 | A | 11 | 36 | U |
| 394 | A | 25 | 96 | U |
| 409 | B | 77 | 56 | U |
| 415 | A | 1 | 51 | U |
CLL indicates chronic lymphocytic leukemia; NA, not available; M, mutated; and U, unmutated.
Patients treated during the course of the disease but were untreated for 3 months prior to blood collection (n = 6).